106 results
S-3ASR
AKRO
Akero Therapeutics Inc
10 May 24
Automatic shelf registration
4:57pm
by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. Our lead product candidate, efruxifermin, or EFX … , characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. Our lead product candidate
8-K
EX-99.1
AKRO
Akero Therapeutics Inc
10 May 24
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
7:17am
, including improvements in lipoprotein risk factors linked to cardiovascular disease – the leading cause of death in MASH patients. EFX is designed … and injury to liver cells, leading to inflammation and fibrosis, which can progress to cirrhosis, liver failure, cancer and eventually death. MASH
PRE 14A
AKRO
Akero Therapeutics Inc
16 Apr 24
Preliminary proxy
4:30pm
, or until his or her earlier death, resignation or removal;
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public
424B5
ijjkkk2n5vsvqk
6 Mar 24
Prospectus supplement for primary offering
5:16pm
424B5
pxva1p984b
4 Mar 24
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
udprzbd54lwv30gw
4 Mar 24
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
7:55am
8-K
EX-99.2
ct7z9
4 Mar 24
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
7:55am
8-K
EX-99.1
gemjmepcg69kmrt38 ci
29 Feb 24
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7:15am
8-K
EX-99.1
4d810nivn6049
18 Dec 23
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
7:08am
8-K
EX-99.1
ynm gd8rre
13 Nov 23
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:15am
8-K
vuuqvrbcm
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
EX-99.1
o7gb4q3acu
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
EX-99.2
rgto7w
10 Oct 23
Regulation FD Disclosure
8:04am
8-K
EX-99.1
brido63r56d9p tdsehe
11 Aug 23
Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
6:09am
8-K
qlvoumlrf 34
26 Jun 23
Submission of Matters to a Vote of Security Holders
4:02pm